Orris

Goal calculation in hypotension pt and uf rate

Reading File
Finding Sources
Finding Sources
Searching PubMed

hemodialysis AND ultrafiltration

Searching the Web

hemodialysis ultrafiltration rate hypotension fluid removal goal guidelines

For intermittent hemodialysis, calculate the UF goal as:
[ \textbf{UF goal (mL)} = (\text{pre-HD weight} - \text{target/dry weight}) \times 1000
  • \text{anticipated intradialytic intake}
  • \text{anticipated urine output} ]
Include intradialytic intake: saline flushes/boluses, IV medications, blood products, tube feeds, and any planned fluid infusion.
[ \textbf{UF rate (mL/h)}=\frac{\text{total UF goal (mL)}}{\text{planned treatment time (h)}} ]
[ \textbf{Weight-adjusted UFR (mL/kg/h)} =\frac{\text{UF goal (mL)}}{\text{time (h)}\times\text{post-HD/target weight (kg)}} ]

In a hypotensive patient

If the patient is currently symptomatic or significantly hypotensive, the immediate approach is usually:
  1. Set UF to 0 or markedly reduce it
  2. Lay flat/Trendelenburg as appropriate
  3. Give prescribed isotonic saline bolus
  4. Reassess BP, symptoms, lung exam, volume status, and the accuracy of target weight
  5. Recalculate a lower, staged UF goal, rather than forcing removal to dry weight during that session
Excessive UF is a common cause of intradialytic hypotension. Textbook guidance describes immediate management as reducing or stopping UF and restoring circulating volume with isotonic saline. It also recommends realistic UF targets and longer treatment time to lower the hourly UF rate. Harrison's notes that rapid fluid removal above 13 mL/kg/h should be avoided, and risk of hypotension/adverse outcomes rises even above roughly 10 mL/kg/h. A current UK Kidney guideline also supports accepting staged target-weight achievement or extending/augmenting dialysis when needed rather than using excessive UFR (UK Kidney guidance).

Example

  • Pre-HD weight: 72.0 kg
  • Target weight: 70.0 kg
  • Expected saline/medication volume: 300 mL
  • Expected urine: 0 mL
  • Session time: 4 h
[ (72 - 70)\times1000 +300 = \textbf{2300 mL UF goal} ]
[ 2300/4 = \textbf{575 mL/h} ]
Using target weight 70 kg:
[ 575/70 = \textbf{8.2 mL/kg/h} ]
If the patient becomes hypotensive, do not continue 575 mL/h automatically. Stop/reduce UF, account for any rescue saline already given, and consider a lower goal, longer run, or an extra session. For example, if 300 mL saline was given for hypotension and the revised plan is to remove only 1.0 L net over the remaining treatment, total machine UF must be adjusted according to remaining time and all fluids already administered.
Quick practical point: “UF goal” is the total machine volume to remove; “net fluid removal” is what the patient actually loses after subtracting all fluids infused during dialysis.
This should be individualized by the dialysis prescriber, particularly with active shock, sepsis, cardiac ischemia, poor cardiac reserve, or recurrent intradialytic hypotension.

Erythropoietin in detail cover aims cre mechanisms indications contradiction dose whole detail

Reading File
Finding Sources
Finding Sources
Searching PubMed

erythropoietin AND chronic kidney disease

Searching the Web

FDA erythropoiesis stimulating agents prescribing information contraindications dosing CKD cancer

Reading File
Finding Sources
Finding Sources
Reading Web Page

https://www.fda.gov/drugs/drug-safety-and-availability/fda-d…

Erythropoietin can mean the normal renal hormone or the therapeutic erythropoiesis-stimulating agents (ESAs) such as epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta. The clinical focus is usually ESA use for anemia, especially CKD-related anemia.
Key areas are:
  1. Physiology: source, regulation by hypoxia/HIF, and action on erythroid marrow
  2. Mechanism and effects: EPO receptor signaling, reticulocyte and hemoglobin response
  3. Aims of treatment: reduce symptoms and RBC transfusion need, not normalize hemoglobin
  4. Preparations and comparison: epoetin alfa, darbepoetin alfa, CERA
  5. Indications: CKD, chemotherapy-associated anemia, zidovudine-associated anemia, selected elective surgery
  6. Assessment before treatment: iron studies, B12/folate, bleeding/inflammation, blood pressure
  7. Doses and adjustment: CKD on dialysis and not on dialysis, cancer-related anemia, response monitoring
  8. Contraindications, precautions, and adverse effects: uncontrolled hypertension, thrombosis/stroke, PRCA, cancer risks
  9. Monitoring and ESA hyporesponsiveness
  10. Practical dialysis points and exam tables
A central safety principle: use the lowest effective dose to reduce transfusion requirements. In CKD, higher hemoglobin targets, especially above 11 g/dL, increase cardiovascular and thrombotic risk according to FDA prescribing information. ESAs are contraindicated in uncontrolled hypertension, prior ESA-associated pure red-cell aplasia, and serious hypersensitivity.
Which part do you want in full detail first?
Asking for Preferences

Which erythropoietin section should I cover in detail first?

This is a shared conversation. Sign in to Orris to start your own chat.